NovaBridge Biosciences insider reports initial holdings

NovaBridge Biosciences executive Xu Cong Claire filed an initial ownership report detailing current equity interests in the company.

Rhea-AI Filing Summary

NovaBridge Biosciences executive Xu Cong Claire filed an initial ownership report detailing current equity interests in the company. The filing lists several employee share options over Ordinary Shares granted between 2021 and 2024 at exercise prices ranging from $60.7000 to $1.0500, with expirations extending to 2034. It also discloses restricted share units that each represent a right to receive one American Depositary Share, and a direct holding of 288,266 Ordinary Shares. The derivative awards include both fully vested options and grants that vest over time according to specified multi‑year schedules.

Insider Trade Summary

8 transactions reported

Mixed 8 txns

Insider Xu Cong Claire

Role See remarks

Type	Security	Shares	Price	Value
holding	2021 Employee Share Option (right to buy)	--	--	--
holding	2022 Employee Share Option (right to buy)	--	--	--
holding	2023 Employee Share Option (right to buy)	--	--	--
holding	2024 Employee Share Option (right to buy)	--	--	--
holding	2024 Employee Share Option (right to buy)	--	--	--
holding	Restricted Share Units	--	--	--
holding	Restricted Share Units	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: 2021 Employee Share Option (right to buy) — 22,900 contracts (Direct); 2022 Employee Share Option (right to buy) — 43,690 contracts (Direct); 2023 Employee Share Option (right to buy) — 57,660 contracts (Direct); 2024 Employee Share Option (right to buy) — 199,030 contracts (Direct); Restricted Share Units — 42,121 contracts (Direct); Ordinary Shares — 288,266 shares (Direct)

Footnotes (10)

1. F1. The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
2. F2. Reported securities are represented by 123,594 ADSs.
3. F3. Number of underlying securities and exercise price expressed in terms of ADSs.
4. F4. The option was granted on July 21, 2021 and is fully vested and exercisable.
5. F5. The option was granted on March 4, 2022 and is fully vested and exercisable.
6. F6. The option was granted on January 4, 2023. The option vests and becomes exercisable in four equal annual installments beginning on the first anniversary of the grant date.
7. F7. The option to purchase 195,820 ADSs was granted on May 30, 2024. The option vested or shall vest and become exercisable over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 30th day of each third month. Amount of underlying securities excludes a portion of the option that has vested and been exercised.
8. F8. The option was granted on September 3, 2024 and is fully vested and exercisable. Amount of underlying securities excludes a portion of the option that has vested and been exercised.
9. F9. On May 30, 2024, the Reporting Person was granted 65,270 restricted share units ("RSUs"). Each RSU represents a contingent right to receive one ADS. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 30th day of each third month.
10. F10. On January 4, 2023, the Reporting Person was granted 21,620 RSUs. The RSUs vested or shall vest in four equal annual installments beginning on the first anniversary of the grant date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the NovaBridge Biosciences (NBP) Form 3 filing show for Xu Cong Claire?

The Form 3 shows Xu Cong Claire’s existing equity interests in NovaBridge Biosciences, including multiple employee share options, restricted share units tied to ADSs, and 288,266 directly held Ordinary Shares, establishing a baseline of insider ownership at the time of becoming a reporting person.

What stock options does Xu Cong Claire hold in NovaBridge Biosciences (NBP)?

Xu Cong Claire holds several employee share options over Ordinary Shares from 2021, 2022, 2023 and 2024 grants, with exercise prices from $60.7000 down to $1.0500 and expirations through 2034, reflecting both fully vested and time‑vested option awards.

How are American Depositary Shares related to NovaBridge Biosciences (NBP) Ordinary Shares in this filing?

The filing explains that NovaBridge Ordinary Shares may be represented by ADSs, where each 10 ADSs represent 23 Ordinary Shares. Reported securities in the Form 3 correspond to 123,594 ADSs, with option and RSU terms expressed in ADS equivalents according to the footnotes.

What restricted share units does Xu Cong Claire report for NovaBridge Biosciences (NBP)?

Xu Cong Claire reports RSUs granted in 2023 and 2024. Each RSU represents a contingent right to receive one ADS, with vesting schedules over four years, typically starting on the first anniversary of the grant date and continuing through quarterly or annual installments.

Does the NovaBridge Biosciences (NBP) Form 3 indicate any recent insider buying or selling?

No specific buy or sell transactions are identified. The entries are categorized as holdings with unknown transaction codes, indicating the Form 3 serves to disclose existing options, RSUs and share ownership rather than report new market purchases or sales.

What portion of Xu Cong Claire’s NovaBridge (NBP) options are already exercisable?

Footnotes clarify that the 2021 and 2022 options, and a 2024 September 3, 2024 grant, are fully vested and exercisable. Other 2023 and 2024 option and RSU grants vest over multi‑year schedules starting on their first anniversaries, creating a mix of vested and unvested interests.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 09:35 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Xu Cong Claire

(Last) (First) (Middle)

C/O NOVABRIDGE BIOSCIENCES,

2440 RESEARCH BOULEVARD, SUITE 400

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
NovaBridge Biosciences [ NBP ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See remarks

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares(1)	288,266(2)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
2021 Employee Share Option (right to buy)	(4)	06/08/2031	Ordinary Shares(1)	22,900(3)	$60.7(3)	D
2022 Employee Share Option (right to buy)	(5)	03/04/2032	Ordinary Shares(1)	43,690(3)	$21.15(3)	D
2023 Employee Share Option (right to buy)	(6)	07/04/2032	Ordinary Shares(1)	57,660(3)	$5.55(3)	D
2024 Employee Share Option (right to buy)	(7)	05/30/2034	Ordinary Shares(1)	146,865(3)(7)	$1.74(3)	D
2024 Employee Share Option (right to buy)	(8)	09/03/2034	Ordinary Shares(1)	52,165(3)	$1.05(3)	D
Restricted Share Units	(9)	(9)	Ordinary Shares(1)	36,716(3)	(9)	D
Restricted Share Units	(10)	(10)	Ordinary Shares(1)	5,405(3)	(10)	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.

2. Reported securities are represented by 123,594 ADSs.

3. Number of underlying securities and exercise price expressed in terms of ADSs.

4. The option was granted on July 21, 2021 and is fully vested and exercisable.

5. The option was granted on March 4, 2022 and is fully vested and exercisable.

6. The option was granted on January 4, 2023. The option vests and becomes exercisable in four equal annual installments beginning on the first anniversary of the grant date.

7. The option to purchase 195,820 ADSs was granted on May 30, 2024. The option vested or shall vest and become exercisable over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 30th day of each third month. Amount of underlying securities excludes a portion of the option that has vested and been exercised.

8. The option was granted on September 3, 2024 and is fully vested and exercisable. Amount of underlying securities excludes a portion of the option that has vested and been exercised.

9. On May 30, 2024, the Reporting Person was granted 65,270 restricted share units ("RSUs"). Each RSU represents a contingent right to receive one ADS. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 30th day of each third month.

10. On January 4, 2023, the Reporting Person was granted 21,620 RSUs. The RSUs vested or shall vest in four equal annual installments beginning on the first anniversary of the grant date.

Remarks:

Senior Vice President, Clinical Development Exhibit List: Ex. 24.1 - Power of Attorney

	/s/ Xi-Yong (Sean) Fu as attorney-in-fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)